Literature DB >> 21509257

Antioxidant status, C-reactive protein and iron status in patients with pulmonary tuberculosis.

Dhia A Taha1, Imad A-J Thanoon.   

Abstract

OBJECTIVES: The objective of this study was to evaluate the influence of acute pulmonary tuberculosis and the effect of drug therapy on markers of oxidative stress (malondialdehyde [MDA] and total antioxidant status [TAS]), C-reactive protein (CRP) and iron body status indices.
METHODS: Forty patients with active pulmonary tuberculosis from the Advisory Clinic for Chest and Respiratory Diseases in Mosul City, Iraq, were included in this study, with fifty healthy age and sex matched subjects as controls. Assessment of serum concentrations of MDA, TAS, CRP, serum iron, total iron binding capacity, transferring saturation percent and ferritin were done for both patients and controls. After two months of therapy with a daily dose of isoniazid 75 mg, rifampicin 150mg, pyraziamide 400 mg, and ethambutol 275 mg, the same parameters were reassessed for the patients.
RESULTS: After two months of therapy, there was a significant reduction in the levels of MDA, CRP, and ferritin, with a significant increase in the TAS, serum iron, and transferring saturation percentage with an insignificant effect on the total iron binding capacity in comparison with the patients' pre-therapy values.
CONCLUSION: Active pulmonary tuberculosis is associated with oxidative stress; the increase in the levels of CRP indicated that pulmonary tuberculosis is associated with an inflammatory response. The initial two months therapy led to significant improvement in oxidative stress and suppression of inflammatory responses. Newly diagnosed cases of pulmonary tuberculosis often had chronic anaemia of inflammation, but this therapy resulted in a significant correction of such anaemia.

Entities:  

Keywords:  C-reactive protein; Iron status; Oxidant/antioxidant status; Pulmonary tuberculosis

Year:  2010        PMID: 21509257      PMCID: PMC3074724     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  27 in total

Review 1.  Control of iron metabolism in Mycobacterium tuberculosis.

Authors:  G Marcela Rodriguez
Journal:  Trends Microbiol       Date:  2006-06-06       Impact factor: 17.079

2.  Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment.

Authors:  T Nguyen-Khoa; Z A Massy; J P De Bandt ; M Kebede; L Salama; G Lambrey; V Witko-Sarsat; T B Drüeke; B Lacour; M Thévenin
Journal:  Nephrol Dial Transplant       Date:  2001-02       Impact factor: 5.992

3.  Haematological abnormalities in children with tuberculosis.

Authors:  G Wessels; H S Schaaf; N Beyers; R P Gie; E Nel; P R Donald
Journal:  J Trop Pediatr       Date:  1999-10       Impact factor: 1.165

4.  A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates.

Authors:  N J Miller; C Rice-Evans; M J Davies; V Gopinathan; A Milner
Journal:  Clin Sci (Lond)       Date:  1993-04       Impact factor: 6.124

Review 5.  Iron, infections, and anemia of inflammation.

Authors:  R L Jurado
Journal:  Clin Infect Dis       Date:  1997-10       Impact factor: 9.079

6.  Increased serum concentrations of conjugated diens and malondialdehyde in patients with pulmonary tuberculosis.

Authors:  S Kwiatkowska; G Piasecka; M Zieba; W Piotrowski; D Nowak
Journal:  Respir Med       Date:  1999-04       Impact factor: 3.415

7.  Circulating markers of free radical activity in patients with pulmonary tuberculosis.

Authors:  C I Jack; M J Jackson; C R Hind
Journal:  Tuber Lung Dis       Date:  1994-04

8.  Effect of iron supplementation on mild to moderate anaemia in pulmonary tuberculosis.

Authors:  Bhabani S Das; Uma Devi; C Mohan Rao; Vinod K Srivastava; Pramod K Rath; Bhabani S Das
Journal:  Br J Nutr       Date:  2003-09       Impact factor: 3.718

9.  Haematological and iron-related measurements in active pulmonary tuberculosis.

Authors:  R D Baynes; H Flax; T H Bothwell; W R Bezwoda; A P MacPhail; P Atkinson; D Lewis
Journal:  Scand J Haematol       Date:  1986-03

10.  Day-to-day variation in iron status indexes is similar for most measures in elderly women with and without rheumatoid arthritis.

Authors:  C J Lammi-Keefe; E S Lickteig; N Ahluwalia; N R Haley
Journal:  J Am Diet Assoc       Date:  1996-03
View more
  6 in total

1.  Effects of treatment on free radicals in patients with pulmonary tuberculosis in South Western Nigeria.

Authors:  Wasiu Olalekan Adebimpe; Ayodeji Oluwaseun Faremi; Sulaiman Adebayo Nassar
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

2.  Biomarkers of oxidative stress and personalized treatment of pulmonary tuberculosis: emerging role of gamma-glutamyltransferase.

Authors:  Etienne Mokondjimobe; Benjamin Longo-Mbenza; Jean Akiana; Ulrich Oswald Ndalla; Regis Dossou-Yovo; Joseph Mboussa; Henri-Joseph Parra
Journal:  Adv Pharmacol Sci       Date:  2012-05-07

3.  The association between tuberculosis and the development of insulin resistance in adults with pulmonary tuberculosis in the Western sub-district of the Cape Metropole region, South Africa: a combined cross-sectional, cohort study.

Authors:  Lauren Philips; Janicke Visser; Daan Nel; Renée Blaauw
Journal:  BMC Infect Dis       Date:  2017-08-15       Impact factor: 3.090

Review 4.  A Dual Role of Heme Oxygenase-1 in Tuberculosis.

Authors:  Sen Yang; Jing Ouyang; Yanqiu Lu; Vijay Harypursat; Yaokai Chen
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

5.  Mean platelet volume as an inflammation marker in active pulmonary tuberculosis.

Authors:  Gulsah Gunluoglu; Esra Ertan Yazar; Nurdan Simsek Veske; Ekrem Cengiz Seyhan; Sedat Altin
Journal:  Multidiscip Respir Med       Date:  2014-02-28

Review 6.  Modulating Iron for Metabolic Support of TB Host Defense.

Authors:  James J Phelan; Sharee A Basdeo; Simone C Tazoll; Sadhbh McGivern; Judit R Saborido; Joseph Keane
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.